Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease
Public ClinicalTrials.gov record NCT01753401. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 4 study is being performed to examine the effects of Acthar for the indicated use of treatment of SLE. This study will enroll patients with steroid-dependent, persistently active SLE with arthritic and/or cutaneous involvement. The study will involve two periods: an 8-week double-blind period, to provide placebo-controlled safety, efficacy, and pharmacodynamic data, and an optional open-label period, to examine the prolonged effects of Acthar maintenance.
Study identification
- NCT ID
- NCT01753401
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 38 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2012
- Primary completion
- Sep 30, 2015
- Completion
- Sep 30, 2015
- Last update posted
- Feb 26, 2020
2013 – 2015
United States locations
- U.S. sites
- 22
- U.S. states
- 10
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mallinckrodt Investigational Site | Jonesboro | Arkansas | 72401 | — |
| Mallinckrodt Investigational Site | La Jolla | California | 92037 | — |
| Mallinckrodt Investigational Site | La Palma | California | 90623 | — |
| Mallinckrodt Investigational Site | Long Beach | California | 90806 | — |
| Mallinckrodt Investigational Site | Upland | California | 91786 | — |
| Mallinckrodt Investigational Site | Brandon | Florida | 33511 | — |
| Mallinckrodt Investigational Site | Clearwater | Florida | 33765 | — |
| Mallinckrodt Investigational Site | Miami Lakes | Florida | 33014 | — |
| Mallinckrodt Investigational Site | Orlando | Florida | 32806 | — |
| Mallinckrodt Investigational Site | Tampa | Florida | 33614 | — |
| Mallinckrodt Investigational Site | Granger | Indiana | 46530 | — |
| Mallinckrodt Investigational Site | Baton Rouge | Louisiana | 70809 | — |
| Mallinckrodt Investigational Site | Lansing | Michigan | 48910 | — |
| Mallinckrodt Investigational Site | Lansing | Michigan | 48917 | — |
| Mallinckrodt Investigational Site | Brooklyn | New York | 11201 | — |
| Mallinckrodt Investigational Site | Great Neck | New York | 11020 | — |
| Mallinckrodt Investigational Site | New York | New York | 10016 | — |
| Mallinckrodt Investigational Site | Charlotte | North Carolina | 28210 | — |
| Mallinckrodt Investigational Site | Hershey | Pennsylvania | 17033 | — |
| Mallinckrodt Investigational Site | Wyomissing | Pennsylvania | 19610 | — |
| Mallinckrodt Investigational Site | Houston | Texas | 77004 | — |
| Mallinckrodt Investigational Site | Houston | Texas | 77034 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01753401, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 26, 2020 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01753401 live on ClinicalTrials.gov.